



15

**YEARS IN**  
**CANADA AND STILL**  
*COUNTING!*<sup>1</sup>



*Celebrating 15 years in Canada and*  
**Over 1.1 million**  
*patient-years of experience worldwide*  
*combined across all indications*<sup>1,3</sup>

XOLAIR® (omalizumab) is indicated for:

- Adult and pediatric patients (6 years of age and above) with moderate to severe persistent asthma who have a positive skin test or *in vitro* reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
- The treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria (CIU) who remain symptomatic despite H1 antihistamine treatment.

Please consult the Product Monograph at [www.novartis.ca/XolairMonograph](http://www.novartis.ca/XolairMonograph) for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, conditions of clinical use, and dosage and administration information. The Product Monograph is also available by calling 1-800-363-8883.

**References:** 1. Notice of Compliance. Health Canada. 2004. 2. XOLAIR® Product Monograph. Novartis Pharmaceuticals Canada Inc., January 23, 2019. 3. Novartis Data on File. 2020.

# Thank you doctor

for considering XOLAIR® (omalizumab)  
for your uncontrolled moderate to severe  
persistent allergic asthma patients.<sup>2</sup>

Sincerely,

*Team XOLAIR®*

Pr **Xolair**  
omalizumab

Comments? Let us know by reaching out  
to your dedicated Novartis contact.